

Gema Moreno-Bueno

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4803973/gema-moreno-bueno-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

11,666
citations

53
h-index

107
g-index

121
ext. papers

13,079
ext. citations

8.2
avg, IF

5.79
L-index

#	Paper	IF	Citations
118	Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival.. <i>Cancers</i> , 2022 , 14,	6.6	4
117	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. <i>Clinical Epigenetics</i> , 2021 , 13, 52	7.7	4
116	E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer. <i>Cancer Research</i> , 2021 , 81, 4529-4544	10.1	3
115	Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer. <i>Cells</i> , 2020 , 9,	7.9	7
114	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
113	Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
112	Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020 , 110, 105003	4.4	7
111	Insight updating of the molecular hallmarks in ovarian carcinoma. <i>European Journal of Cancer, Supplement</i> , 2020 , 15, 16-26	1.6	4
110	Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis. <i>International Journal of Medical Sciences</i> , 2020 , 17, 2987-2997	3.7	2
109	Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. <i>Clinical Cancer Research</i> , 2019 , 25, 4846-4858	12.9	32
108	Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	26
107	Therapeutic targeting of HER2-CBR heteromers in HER2-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 3863-3872	11.5	27
106	Exosome-mimetic nanoplatforms for targeted cancer drug delivery. <i>Journal of Nanobiotechnology</i> , 2019 , 17, 85	9.4	73
105	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. <i>Oncogene</i> , 2019 , 38, 6035-6050	9.2	34
104	Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells. <i>Cancers</i> , 2019 , 12,	6.6	3
103	Prostaglandin F-induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity. <i>Neoplasia</i> , 2019 , 21, 1073-1084	6.4	5
102	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2019 , 11,	6.6	16

101	In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. <i>Carcinogenesis</i> , 2018 , 39, 447-457	4.6	10
100	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. <i>Pathobiology</i> , 2018 , 85, 35-40	3.6	10
99	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 532-543	6.1	19
98	The Ras-related gene ERAS is involved in human and murine breast cancer. <i>Scientific Reports</i> , 2018 , 8, 13038	4.9	11
97	EMT: Present and future in clinical oncology. <i>Molecular Oncology</i> , 2017 , 11, 718-738	7.9	148
96	LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. <i>Scientific Reports</i> , 2017 , 7, 44988	4.9	60
95	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017 , 36, 2737-2749	9.2	27
94	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. <i>International Journal of Cancer</i> , 2017 , 140, 1551-1563	7.5	21
93	Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. <i>Cell Reports</i> , 2017 , 21, 154-167	10.6	76
92	Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 5846-5859	10.1	84
91	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. <i>Modern Pathology</i> , 2017 , 30, 134-145	9.8	21
90	Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , 2017 , 241, 475-487	9.4	31
89	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , 2016 , 10, 137-49	8.8	29
88	Biological Effects of Temezirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study. <i>International Journal of Gynecological Cancer</i> , 2016 ,	3.5	4
87	The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. <i>Oncogene</i> , 2016 , 35, 3485-94	9.2	10
86	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016 , 7, 56295-56308	3.3	38
85	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. <i>Oncotarget</i> , 2016 , 7, 60110-60122	3.3	13
84	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016 , 8, 88	14.4	5

83	Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. <i>EMBO Journal</i> , 2015 , 34, 1090-109	13	56
82	Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors. <i>Carcinogenesis</i> , 2015 , 36, 585-97	4.6	5
81	Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv077	9.7	69
80	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , 2015 , 28, 1492-503	9.8	14
79	Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. <i>Oncogene</i> , 2015 , 34, 951-64	9.2	65
78	Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. <i>International Journal of Cancer</i> , 2015 , 136, E62-73	7.5	41
77	EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. <i>Oncogene</i> , 2015 , 34, 2609-20	9.2	71
76	Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , 2015 , 136, 1863-73	7.5	30
75	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. <i>BMC Cancer</i> , 2015 , 15, 940	4.8	12
74	Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. <i>Oncotarget</i> , 2015 , 6, 38239-56	3.3	25
73	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. <i>Journal of Pathology</i> , 2014 , 232, 319-29	9.4	58
72	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. <i>Human Pathology</i> , 2014 , 45, 2394-403	3.7	13
71	MicroRNAs as prognostic markers in ovarian cancer. <i>Molecular and Cellular Endocrinology</i> , 2014 , 390, 73-84	4.4	27
70	ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. <i>Oncogene</i> , 2014 , 33, 1945-53	9.2	14
69	Gasdermin-B promotes invasion and metastasis in breast cancer cells. <i>PLoS ONE</i> , 2014 , 9, e90099	3.7	67
68	Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. <i>Cancer Management and Research</i> , 2014 , 6, 205-16	3.6	123
67	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014 , 13, 223	42.1	72
66	LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. <i>Biology Open</i> , 2014 , 3, 129-37	2.2	40

65	Sin3b interacts with Myc and decreases Myc levels. <i>Journal of Biological Chemistry</i> , 2014 , 289, 22221-36	5.4	21
64	MicroRNA-dependent regulation of transcription in non-small cell lung cancer. <i>PLoS ONE</i> , 2014 , 9, e90524	4.7	53
63	Endometrial carcinoma: molecular alterations involved in tumor development and progression. <i>Oncogene</i> , 2013 , 32, 403-13	9.2	126
62	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. <i>Human Pathology</i> , 2013 , 44, 244-54	3.7	28
61	E47 and Id1 interplay in epithelial-mesenchymal transition. <i>PLoS ONE</i> , 2013 , 8, e59948	3.7	39
60	Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. <i>Cancer Cell</i> , 2012 , 22, 709-24	24.3	692
59	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. <i>Nature Medicine</i> , 2012 , 18, 883-91	50.5	2530
58	The EMT signaling pathways in endometrial carcinoma. <i>Clinical and Translational Oncology</i> , 2012 , 14, 715-20	3.6	76
57	LOXL2 in epithelial cell plasticity and tumor progression. <i>Future Oncology</i> , 2012 , 8, 1095-108	3.6	71
56	The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. <i>Oncogene</i> , 2012 , 31, 2049-61	9.2	52
55	KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. <i>American Journal of Pathology</i> , 2011 , 178, 1529-43	5.8	30
54	A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. <i>PLoS ONE</i> , 2011 , 6, e23302	3.7	54
53	The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. <i>Aging Cell</i> , 2011 , 10, 158-71	9.9	28
52	Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , 2011 , 223, 72-80	9.4	175
51	Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. <i>EMBO Molecular Medicine</i> , 2011 , 3, 528-44	12	130
50	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. <i>Molecular Cancer</i> , 2010 , 9, 196	42.1	119
49	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <i>Clinical Cancer Research</i> , 2009 , 15, 2711-22	12.9	138
48	Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 12962-7	11.5	36

47	The class I bHLH factors E2-2A and E2-2B regulate EMT. <i>Journal of Cell Science</i> , 2009 , 122, 1014-24	5.3	94
46	Functional characterization of E- and P-cadherin in invasive breast cancer cells. <i>BMC Cancer</i> , 2009 , 9, 74	4.8	50
45	The morphological and molecular features of the epithelial-to-mesenchymal transition. <i>Nature Protocols</i> , 2009 , 4, 1591-613	18.8	165
44	Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1157-63	6.7	60
43	Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. <i>Modern Pathology</i> , 2008 , 21, 925-36	9.8	19
42	Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. <i>Oncogene</i> , 2008 , 27, 4690-701	9.2	86
41	JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. <i>Oncogene</i> , 2008 , 27, 5033-44	9.2	53
40	Transcriptional regulation of cell polarity in EMT and cancer. <i>Oncogene</i> , 2008 , 27, 6958-69	9.2	459
39	PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. <i>Breast Cancer Research</i> , 2008 , 10, R100	8.3	22
38	Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. <i>Cancer Research</i> , 2008 , 68, 4541-50	10.1	158
37	Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. <i>Cancer Research</i> , 2008 , 68, 989-97	10.1	823
36	"New" molecular taxonomy in breast cancer. <i>Clinical and Translational Oncology</i> , 2008 , 10, 777-85	3.6	13
35	Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. <i>Proteomics - Clinical Applications</i> , 2008 , 2, 1313-26	3.1	8
34	Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. <i>Oncogene</i> , 2007 , 26, 2902-13	9.2	108
33	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. <i>Modern Pathology</i> , 2007 , 20, 474-81	9.8	179
32	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 157-72	4.4	59
31	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. <i>Journal of Clinical Pathology</i> , 2007 , 60, 1006-12	3.9	78
30	SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. <i>Cancer Research</i> , 2007 , 67, 11721-31	10.1	160

29	Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. <i>Cancer Research</i> , 2007 , 67, 1927-34	10.1	95
28	Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 501-8	6.7	53
27	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5SDFUR in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2006 , 72, 1646-56	6	25
26	Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. <i>International Journal of Cancer</i> , 2006 , 119, 1164-75	7.5	61
25	Low frequency of BRAF mutations in endometrial and in cervical carcinomas. <i>Clinical Cancer Research</i> , 2006 , 12, 3865; author reply 3865-6	12.9	19
24	Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. <i>Cancer Research</i> , 2006 , 66, 9543-56	10.1	259
23	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. <i>Human Pathology</i> , 2006 , 37, 1042-9	3.7	63
22	High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. <i>Journal of Pathology</i> , 2006 , 208, 708-13	9.4	60
21	Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). <i>American Journal of Surgical Pathology</i> , 2005 , 29, 1322-9	6.7	67
20	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. <i>Clinical Cancer Research</i> , 2004 , 10, 6487-501	12.9	257
19	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. <i>Oncogene</i> , 2004 , 23, 3272-83	9.2	167
18	Re: Scholten et al. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. <i>J Pathol</i> 2003; 201: 460-465. <i>Journal of Pathology</i> , 2004 , 202, 511-2	9.4	7
17	Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. <i>International Journal of Cancer</i> , 2004 , 110, 194-200	7.5	30
16	Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. <i>International Journal of Cancer</i> , 2003 , 106, 208-15	7.5	149
15	Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. <i>Journal of Pathology</i> , 2003 , 199, 471-8	9.4	107
14	Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2003 , 201, 589-95	9.4	48
13	Cyclin D1 gene (CCND1) mutations in endometrial cancer. <i>Oncogene</i> , 2003 , 22, 6115-8	9.2	88
12	Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. <i>Modern Pathology</i> , 2003 , 16, 1148-58	9.8	32

11	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. <i>Oncogene</i> , 2002 , 21, 3241-6	9.2	478
10	Abnormalities of the APC/beta-catenin pathway in endometrial cancer. <i>Oncogene</i> , 2002 , 21, 7981-90	9.2	228
9	beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. <i>Diagnostic Molecular Pathology</i> , 2001 , 10, 116-22		120
8	Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001 , 438, 464-9	5.1	48
7	beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. <i>British Journal of Dermatology</i> , 2001 , 145, 576-81	4	114
6	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. <i>Cancer</i> , 2001 , 92, 2829-36	6.4	88
5	The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. <i>Modern Pathology</i> , 2001 , 14, 650-4	9.8	74
4	Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. <i>Lung Cancer</i> , 2001 , 34, 67-74	5.9	15
3	Isolation and characterization of casein kinase I from Dictyostelium discoideum. <i>Biochemical Journal</i> , 2000 , 349, 527-37	3.8	3
2	beta-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000 , 437, 599-604	5.1	38
1	beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. <i>American Journal of Pathology</i> , 1999 , 155, 527-36	5.8	195